Get the Stockscreener App
1.51
2.58%
-0.04
After Hours:
1.48
-0.03
-1.99%
Galmed Pharmaceuticals Ltd stock is traded at $1.51, with a volume of 55,513.
It is down -2.58% in the last 24 hours and up +6.34% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.55
Open:
$1.55
24h Volume:
55,513
Relative Volume:
0.19
Market Cap:
$8.27M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4632
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
+11.03%
1M Performance:
+6.34%
6M Performance:
-14.71%
1Y Performance:
-62.06%
1-Day Range:
$1.50
$1.5999
1-Week Range:
$1.335
$1.5999
52-Week Range:
$1.15
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.51 | 7.73M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Can a trend reversal in Galmed Pharmaceuticals Ltd. lead to recoveryJuly 2025 Opening Moves & Weekly High Return Stock Forecasts - Newser
Does Galmed Pharmaceuticals Ltd. fit your quant trading modelWeekly Profit Recap & Precise Swing Trade Entry Alerts - Newser
Market reaction to Galmed Pharmaceuticals Ltd.’s recent newsPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
How high can Galmed Pharmaceuticals Ltd. stock goWeekly Trading Summary & Expert Verified Movement Alerts - Newser
Backtesting results for Galmed Pharmaceuticals Ltd. trading strategiesTrade Performance Summary & Safe Swing Trade Setups - Newser
Signal strength of Galmed Pharmaceuticals Ltd. stock in tech scannersJuly 2025 Gainers & Safe Entry Trade Signal Reports - Newser
Galmed Pharmaceuticals Unveils Digital Asset Strategy and Modifies SEDDS Agreement - MSN
using python tools to backtest galmed pharmaceuticals ltd. strategiesGap Down & High Conviction Buy Zone Picks - Newser
Earnings visualization tools for Galmed Pharmaceuticals Ltd.Portfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Using Python tools to backtest Galmed Pharmaceuticals Ltd. strategies2025 Trading Volume Trends & Entry Point Confirmation Signals - Newser
Tools to monitor Galmed Pharmaceuticals Ltd. recovery probabilityBuy Signal & High Conviction Buy Zone Alerts - Newser
Why Galmed Pharmaceuticals Ltd. is moving todayTrade Risk Summary & Community Shared Stock Ideas - Newser
Statistical indicators supporting Galmed Pharmaceuticals Ltd.’s strengthJuly 2025 Review & Capital Efficiency Focused Strategies - Newser
How to build a custom watchlist for Galmed Pharmaceuticals Ltd.July 2025 Highlights & Community Supported Trade Ideas - Newser
What indicators show strength in Galmed Pharmaceuticals Ltd.Market Volume Summary & Fast Moving Trade Plans - Newser
Is Galmed Pharmaceuticals Ltd. meeting your algorithmic filter criteria2025 Earnings Surprises & Proven Capital Preservation Methods - Newser
Ranking Galmed Pharmaceuticals Ltd. among high performing stocks via tools2025 Key Highlights & Detailed Earnings Play Strategies - Newser
Quantitative breakdown of Galmed Pharmaceuticals Ltd. recent movePortfolio Return Report & Smart Allocation Stock Tips - Newser
Will Galmed Pharmaceuticals Ltd. stock go up soonWeekly Market Outlook & Entry Point Confirmation Signals - Newser
What’s next for Galmed Pharmaceuticals Ltd. stock priceQuarterly Risk Review & Real-Time Buy Zone Alerts - Newser
Will Galmed Pharmaceuticals Ltd. price bounce be sustainableTreasury Yields & Fast Exit and Entry Trade Guides - Newser
Best data tools to analyze Galmed Pharmaceuticals Ltd. stockTrend Reversal & AI Enhanced Execution Alerts - Newser
Tools to assess Galmed Pharmaceuticals Ltd.’s risk profilePortfolio Update Summary & Entry Point Strategy Guides - Newser
How to read the order book for Galmed Pharmaceuticals Ltd.Market Sentiment Summary & Consistent Growth Equity Picks - Newser
Has Galmed Pharmaceuticals Ltd. found a price floorJuly 2025 Update & Fast Exit Strategy with Risk Control - Newser
Using data tools to time your Galmed Pharmaceuticals Ltd. exitDay Trade & Real-Time Market Trend Scan - Newser
Is this a good reentry point in Galmed Pharmaceuticals Ltd.July 2025 Patterns & Community Supported Trade Ideas - Newser
Is Galmed Pharmaceuticals Ltd. stock poised for growthPortfolio Performance Report & Pattern Based Trade Signal System - Newser
How to manage a losing position in Galmed Pharmaceuticals Ltd.Portfolio Return Summary & Low Drawdown Momentum Ideas - Newser
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):